XUND vs ArteraAI
A side-by-side comparison built from both listings. Blank cells mean the company has not given that detail; we never guess.
XUND compared with ArteraAI
| Detail | 
XUND | 
ArteraAI |
|---|
| What it does | AI-powered medical decision support for patients and healthcare professionals
| Personalized precision medicine powered by AI for cancer therapy
|
|---|
| Stage | Established
| Not given
|
|---|
| Founded | 2018
| Not given
|
|---|
| Based in | AT
| US
|
|---|
| Pricing model | Contact for pricing
| Contact for pricing
|
|---|
| Pricing | Not given
| Not given
|
|---|
| Key features | - MDR 2017/745 certification
- ISO 13485:2016 certified quality management
- ISO 27001:2022 security compliance
- De-identified data processing
- German data storage for GDPR compliance
- Multi-language support
| - Analyzes digital pathology with no additional tissue staining required
- Rapid results within 1-2 days after specimen receipt
- Validated across diverse populations including African American and non-African American men
- FDA De Novo authorization for prostate cancer risk stratification
- Insurance coverage for Medicare and many commercial plans
- Provides 5 and 10-year distant metastasis risk for breast cancer
- Identifies breast cancer patients who benefit from chemotherapy
- Included in NCCN Clinical Practice Guidelines for Prostate Cancer
|
|---|
| What makes it different | - API-first certified medical devices that don't require integrators to become device manufacturers
- Medical content verified by in-house doctors using AI and literature review
- Comprehensive symptom coverage with 360+ symptom groups and 21,000+ variations
- European data protection with local German storage and GDPR/HIPAA compliance
- Trusted by leading healthcare organizations across multiple sectors
| - No additional tissue preparation needed, uses existing H&E slides
- Validated across multiple large randomized phase III clinical trials
- FDA De Novo clearance as Software as a Medical Device
- Financial assistance program to make tests affordable regardless of income
|
|---|
| Community votes | 0 | 0 |
|---|
| DR (Domain Rating by Ahrefs) | 38 ● no change since last check | 57 ● no change since last check |
|---|
| Trust Flow (Majestic) | 17 | 15 |
|---|
| Citation Flow (Majestic) | 32 | 27 |
|---|
| Referring domains (Majestic) | 168 | 285 |
|---|
5 details filled in for both companies.
More alternatives to XUND More alternatives to ArteraAI